CG Oncology, Inc. (CGON) AI Stock Analysis

• Market Cap: $1.95B
• Dividend Yield: N/A
• Average Volume (3M): 853.17K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.85
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 113
• Sector: General
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): -0.54
• Shares Outstanding: 76,247,580
• 10 Day Avg. Volume: 571,097
• 30 Day Avg. Volume: 853,175
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.68
• Enterprise Value/Revenue: 2.40K
• Enterprise Value/Gross Profit: 3.35K
• Enterprise Value/Ebitda: -8.41
• 1Y Price Target: $60.57
• Price Target Upside: 137.25% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

• Rating: 45 Neutral
• Price Target: $25.00 ▼(-2.08% Downside)

CG Oncology, Inc. faces significant financial challenges with no current revenue and ongoing losses, impacting its financial performance score. Technical analysis indicates neutral momentum, while valuation metrics reflect typical early-stage biotech characteristics. The company's strong equity base and cash reserves offer some stability, but reliance on external funding poses risks.

Positive Factors

Drug Development

CG Oncology's BLA submission for cretostimogene in BCG-unresponsive HR-NMIBC remains on track, with significant data expected soon.

Financial Stability

Plenty of cash ($661.1M) is available to support the company through the first potential approval and key pivotal readouts.

Trial Enrollment

Accelerated enrollment in trials reflects strong physician confidence and suggests significant uptake potential for cretostimogene.

Negative Factors

Investor Sentiment

The short interest in CG Oncology is 24%, indicating some skepticism among investors.

Regulatory Challenges

Despite positive topline data from phase 2 CORE-008 cohort A, the results are not sufficient for registration, requiring a much larger trial.

CG Oncology, Inc. Business Overview & Revenue Model

Company Description

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

How the Company Makes Money

CG Oncology, Inc. makes money primarily through the development and commercialization of its proprietary oncolytic immunotherapy treatments. The company's revenue model includes the potential for milestone payments, royalties, and licensing fees from partnerships with larger pharmaceutical companies. These partnerships may involve collaborative research and development agreements or licensing agreements for the distribution and marketing of CG Oncology's therapies. Additionally, the company may pursue direct commercialization of its products, subject to successful clinical trials and regulatory approval, to generate revenue through product sales.

CG Oncology, Inc. Financial Statement Overview

Summary

CG Oncology, Inc. is facing financial challenges typical of early-stage biotechnology firms, with no current revenue and significant operating losses. The strong equity position and cash reserves provide some stability, but the reliance on external funding indicates potential risks if capital markets shift. The company’s focus should be on achieving revenue growth and improving operational efficiencies to sustain long-term viability.

Income Statement

CG Oncology, Inc. reported zero revenue in the latest year, indicating challenges in generating income. The company has experienced consistent losses with deteriorating EBIT and EBITDA margins, reflecting operational inefficiencies and potential barriers in monetizing its biotechnology developments.

Balance Sheet

The company's strong equity base relative to total assets, demonstrated by a high equity ratio, provides a solid financial foundation. However, the minimal debt levels and high cash reserves suggest limited leverage but also an underutilization of potential financing for growth.

Cash Flow

The negative free cash flow and significant negative operating cash flow highlight ongoing cash burn issues. Despite substantial financing inflows, the company is heavily reliant on external funding for operations, which could pose risks if such funding diminishes.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	551.00K	1.14M	204.00K	191.00K	10.36M
Gross Profit	395.00K	1.14M	204.00K	176.00K	10.35M
EBITDA	-157.24M	-114.63M	-55.43M	-35.23M	-12.38M
Net Income	-86.66M	-88.04M	-48.61M	-35.44M	-12.84M
Balance Sheet
Total Assets	701.45M	754.80M	199.30M	147.75M	58.69M
Cash, Cash Equivalents and Short-Term Investments	661.05M	742.00M	187.67M	143.48M	53.61M
Total Debt	994.00K	238.00K	461.00K	15.94M	15.13M
Total Liabilities	31.09M	21.42M	14.51M	22.57M	18.44M
Stockholders Equity	670.36M	733.38M	184.79M	125.18M	40.25M
Cash Flow
Free Cash Flow	-94.06M	-78.95M	-45.68M	-29.82M	-13.75M
Operating Cash Flow	-93.82M	-78.71M	-45.68M	-29.80M	-13.65M
Investing Cash Flow	-142.45M	-300.76M	-121.19M	-55.35M	-97.00K
Financing Cash Flow	225.74M	628.28M	87.00M	119.69M	15.45M

CG Oncology, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 25.53
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CGON, the sentiment is Positive. The current price of 25.53 is below the 20-day moving average (MA) of 25.78, below the 50-day MA of 26.08, and below the 200-day MA of 27.52, indicating a neutral trend. The MACD of -0.12 indicates Negative momentum. The RSI at 50.83 is Neutral, neither overbought nor oversold. The STOCH value of 68.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CGON.

CG Oncology, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ARQT	58 Neutral	$1.89B	―	-57.33%	―	99.50%	65.91%
IDYA	56 Neutral	$2.11B	―	-35.09%	―	-41.48%	-73.55%
Sector *	55 Neutral	$6.40B	7.52	-10.04%	6.32%	14.96%	-2.21%
CGON	45 Neutral	$1.95B	―	-20.95%	―	―	―
IRON	43 Neutral	$2.02B	―	-26.36%	―	―	-22.19%
BEAM	41 Neutral	$1.65B	―	-41.94%	―	-82.90%	-155.64%
COGT	37 Underperform	$1.64B	―	-107.55%	―	―	2.25%

CG Oncology, Inc. Corporate Events

CG Oncology Appoints Interim CFO After Resignation

CG Oncology, Inc. announced that its Chief Financial Officer, Corleen Roche, has resigned, with her departure effective on August 5, 2025. The company has appointed Robert Lapetina as the interim principal financial and accounting officer, effective the same date, until a permanent replacement is found.

CG Oncology Holds 2025 Annual Stockholders Meeting

On June 5, 2025, CG Oncology, Inc. held its 2025 Annual Meeting of Stockholders where key decisions were made regarding the company’s leadership and auditing practices. The stockholders elected three Class I directors to serve until the 2028 Annual Meeting and ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.